Helping direct the development of nanowire-based biomolecule detection. Semiconductor nanowires can act as nanoscaled optical fibers, enabling them to guide and concentrate light emitted by surface-bound fluorophores by waveguiding, enhancing the sensitivity of optical biosensing significantly.

Responsible for Samplix patent strategy. Samplix develops novel droplet-based enrichment and target selection tools. Our products permit informed research decisions by empowering scientist to sequence any genetic region for the purpose of determining virus integration, excluding unintended CRISPR edits, closing gaps in otherwise inaccessible regions, and more.

Anapa Biotech A/S, develops molecular tools to enable highly multiplexing PCR diagnostics. Our technology offers improvement to areas like human and veterinary diagnostics, food and feed quality and safety, environmental surveillance. For more information, visit the new website at www.anapabiotech.com.

Mirrx Therapeutics A/S holds fundamental IP to a unique technology for modulation of microRNA pathways which enable increasing protein production from specific messenger RNA. The so-called Blockmir compounds developed by Mirrx have relevance for all major disease areas and have a very low risk of unwanted side-effects.

• Responsible for Exiqon’s patent portfolio, in- and outlicensing activites, contract negotiations, research collaborations. • Managing patent department (3 employees) and business development (2 employees)

Managing licensensing cases on Exiqon technology.

Managed the development of Exiqon's java-based GenoView software for genotype readout.

1998-2001Post doc position, Steno Diabetes Center / Hagedorn research Center. Daily co-manager of the research group of over 20 persons. Responsible for the efforts on genetics of obesity in the group. Supervisor function for Ph.D-students in the group. Application of bioinformatics approach to candidate gene studies. Cloning of novel gene-segments. Collection of obese probands and families for genetic studies by TDT and random genotyping as well as mutational analysis of candidate genes.

1995-June1998PhD-student, Steno Diabetes Center, ending June 1998, ”Identification and Molecular Characterisation of Putative Genetic Risk Factors in the Pathogenesis of Obesity and Non-Insulin-Dependent Diabetes Mellitus”